All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Graham Collins from Oxford University Hospitals NHS Foundation Trust, Oxford, UK, asking: in which patients with relapsed/refractory classical Hodgkin lymphoma (cHL) is camidanlumab tesirine most effective?
Graham Collins discusses how camidanlumab tesirine was shown to be highly active in a phase I dose escalation trial, which had very high overall response rates, along with a significant toxicity profile.
In which patients with R/R cHL is camidanlumab tesirine most effective?
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Lymphoma Hub Satellite Symposium 2019 | Chemo-free approaches in MCL - Professor Simon Rule
Professor Simon Rule discussed the novel chemotherapy-free treatment approaches in MCL during the Lymphoma Hub Satellite Symposium at 15-ICML.
ICML 2019 | Which patients with MCL could benefit most from ibrutinib plus rituximab in the front-line setting?
During ICML 2019 in Lugano, the Lymphoma Hub were pleased to speak to Preetesh Jain from MD Anderson Cancer Center, Houston, US, about...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox